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Abstract
Hydrogen sulfide, a signaling molecule formed mainly from cysteine, is catabo-
lized by sulfide:quinone oxidoreductase (gene SQOR). Toxic hydrogen sulfide
exposure inhibits complex IV. We describe children of two families with patho-
genic variants in SQOR. Exome sequencing identified variants; SQOR enzyme
activity was measured spectrophotometrically, protein levels evaluated by
western blotting, and mitochondrial function was assayed. In family A, follow-
ing a brief illness, a 4-year-old girl presented comatose with lactic acidosis and
multiorgan failure. After stabilization, she remained comatose, hypotonic, had
neurostorming episodes, elevated lactate, and Leigh-like lesions on brain
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imaging. She died shortly after. Her 8-year-old sister presented with a rapidly
fatal episode of coma with lactic acidosis, and lesions in the basal ganglia and
left cortex. Muscle and liver tissue had isolated decreased complex IV activity,
but normal complex IV protein levels and complex formation. Both patients
were homozygous for c.637G > A, which we identified as a founder mutation
in the Lehrerleut Hutterite with a carrier frequency of 1 in 13. The resulting p.
Glu213Lys change disrupts hydrogen bonding with neighboring residues,
resulting in severely reduced SQOR protein and enzyme activity, whereas sul-
fide generating enzyme levels were unchanged. In family B, a boy had episodes
of encephalopathy and basal ganglia lesions. He was homozygous for c.446delT
and had severely reduced fibroblast SQOR enzyme activity and protein levels.
SQOR dysfunction can result in hydrogen sulfide accumulation, which, consis-
tent with its known toxicity, inhibits complex IV resulting in energy failure. In
conclusion, SQOR deficiency represents a new, potentially treatable, cause of
Leigh disease.
KEYWORD S
complex IV, hydrogen sulfide, Leigh disease, sulfide:quinone oxidoreductase, treatment
1 | INTRODUCTION
Despite the purported role of hydrogen sulfide (H2S) as a
signaling molecule with multiple physiologic functions,
few inherited disorders have been described involving its
metabolism or function.1,2 Here, we describe a new disor-
der of H2S metabolism.
In brain, H2S increases cAMP, stimulates NMDA-
receptor mediated responses including long-term potenti-
ation, and stimulates calcium influx in astrocytes. In
the vascular system, it promotes vasodilatation and
angiogenesis.1,2 It upregulates antioxidant systems, anti-
inflammatory, and cytoprotective genes.
The toxicity of excess H2S, such as occurs during
exposure in industrial accidents, results in part from
inhibiting cytochrome c oxidase, including by coordina-
tion with the iron of heme a.3 It changes the ventilatory
drive possibly by inhibiting carbonic anhydrase, and can
cause pulmonary edema and cardiac depression.
Chronic H2S accumulation has been implicated in
ethylmalonic encephalopathy and related to inhibition
of short chain acyl-CoA dehydrogenase and loss of
cytochrome c oxidase.4–7 Finally, H2S has been impli-
cated in the pathophysiology of primary coenzyme
Q deficiency.8,9
The metabolism of H2S is complex (Figure 1). At
physiological pH, H2S consists of dissolved gaseous H2S
in equilibrium with HS−. It is primarily generated from
cysteine via the activity of three enzymes. In most tissues,
the majority of H2S production is derived via
α,β-elimination by cystathionine γ-lyase (CTH) upon L-
cysteine to form L-serine and H2S.
10,11 Also, H2S is
formed in the condensation reaction of cystathionine
β-synthase (CBS) when L-serine is substituted by L-cyste-
ine. Further, L-cysteine is transaminated by cysteine ami-
notransferase (CAT) with α-ketoglutarate forming
3-mercaptopyruvate, which is then acted upon by
mercaptopyruvate sulfurtransferase (MPST) to release
H2S in mitochondria and in the cytosol.
12 In the brain, D-
cysteine can be oxidized by D-amino-oxidase to
mercaptopyruvate, the substrate for MPST.12 Finally, gut
bacteria produce H2S, which is rapidly metabolized in
the intestinal epithelium.7,13–15
H2S is primarily oxidized via sulfide:quinone oxido-
reductase, an inner mitochondrial membrane protein
encoded by the SQOR gene (previously called SQRDL)
(OMIM# 617658). A cysteine persulfide is transiently
formed in the SQOR active site while electrons from
H2S oxidation reduce coenzyme Q via the cofactor
FAD.16 The sulfane sulfur from this persulfide interme-
diate is then transferred to the physiological acceptor
glutathione forming glutathione persulfide (GSSH).17,18
In vitro, sulfite, cyanide, and other acceptors can substi-
tute for glutathione forming thiosulfate, thiocyanate,
and other products.17 Glutathione persulfide is oxidized
by persulfide dioxygenase (encoded by the gene ETHE1,
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pathogenic variants in this gene are implicated in
ethylmalonic encephalopathy) to sulfite, which can
be further oxidized to sulfate by sulfite oxidase
or metabolized by thiosulfate sulfurtransferase to
thiosulfate.7
Leigh disease is a frequent neurologic presentation
of genetic defects in mitochondrial bioenergetics.19 It is
highly heterogenous genetically with more than
75 causative genes identified, yet the genetic cause for
many patients remains unresolved.20 Most patients
have defects in structural genes of the respiratory
chain complex, or in processes involving transcription,
translation, or assembly of the protein complexes
including their multiple cofactors. Defects in complex
IV are a recurring cause of Leigh disease.21 Very few
mitochondrial disorders are related to secondary toxic
inhibition of respiratory chain enzyme complexes. Few
mitochondrial disorders have an effective treatment
option.
Here, we present children from two families who
developed Leigh disease. The genetic defect was identi-
fied in the SQOR gene, and functional assays show abro-
gated SQOR enzyme activity and isolated decreased
complex IV activity, but normal complex IV protein
levels and complex formation. Recognition of this new
genetic cause of Leigh disease is clinically important as it
identifies a potentially treatable condition.
2 | METHODS
2.1 | Subjects
All procedures were done in accordance with the ethical
standards of the ethics committee in accordance with the
Helsinki Declaration of 1975 and as revised in 2000. Stud-
ies at the University of Colorado were done following
IRB-approved protocols 07-0386 and 16-0146. Studies at
Shodair Children's Hospital in Montana were done
according to IRB-approved protocol IRB00008287. For
studies of identifiable living human subjects, written
informed consent was obtained prior to initiation of
research as outlined in the IRB-approved study. The
study was approved by the ethics committee of the Uni-
versity of Tuebingen (437/2018BO1). The clinical histo-
ries were reviewed by clinical geneticists, and brain
magnetic resonance imaging (MRI) studies were
reviewed by a pediatric neuroradiologist (D. M.).
2.2 | Exome sequencing
Exome sequencing was performed on the index cases and
their parents. For an initial estimate of the carrier rate in
the Hutterite population, de-identified DNA samples
from this population that had been previously submitted
FIGURE 1 The metabolism of hydrogen sulfide. Hydrogen sulfide (H2S) is formed from cysteine by cystathionine β-synthase (CBS) or
by cystathionine-γ-lyase (CTH), or after transamination via cysteine aminotransferase (CAT) and the action of mercaptopyruvate sulfur
transferase (MPST). Cysteine is also produced by gut bacteria. Cysteine is oxidized by cysteine dioxygenase (CDO) in the pathway to taurine
synthesis. H2S is primarily oxidized by sulfide:quinone oxidoreductase (SQOR) with the electrons transferred to coenzyme Q (CoQ), and
with concomitant sulfur transfer to glutathione (GSH) to form glutathione persulfide (GSSH). GSSH is then oxidized to form sulfite by
persulfide dioxygenase (SDO, gene ETHE1), which is further oxidized to sulfate by sulfite oxidase (SUOX). GSSH can also be converted to
thiosulfate by thiosulfate sulfurtransferase (TST). Accumulating hydrogen sulfide can inhibit respiration at the level of complex IV. Other
abbreviations used: CoQ is oxidized coenzyme Q, CoQH2 is reduced coenzyme Q, Cytc is cytochrome c, α-KG is α-ketoglutarate, SO32− is
sulfite, SO4
2− is sulfate, SSO3
2− is thiosulfate. MPST is variably localized in both the mitochondria and cytosol
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for diagnostic studies for variable indications were
screened by high-resolution melt curve analysis and
Sanger sequencing as described in Supplemental
Methods. The carrier incidence in the general population
was identified from the gnomAD database using a meth-
odology as described in Supplemental Methods.22
2.3 | Analysis of respiratory chain
enzyme activities and assembly
Respiratory chain enzyme activities of complexes I, II, II
+ III, III, IV, and citrate synthase were analyzed in dupli-
cate in post-600× g supernatants isolated from liver and
muscle of subject A.II-3 and from fibroblasts of subject B.
II-3 as described previously.23 Ratios of enzyme activities
to either citrate synthase or complex II activities were cal-
culated and expressed as Z-scores of the normal distribu-
tion established in control samples. Solubilized inner
mitochondrial membrane fractions isolated by differen-
tial centrifugation from liver and muscle from subject A.
II-3 and from fibroblasts from subject B.II-3 were sepa-
rated by blue native polyacrylamide gel electrophoresis
(BN-PAGE) and evaluated by in-gel activity staining
assays as described previously.23
Complex IV assembly was analyzed in isolated mito-
chondrial membrane fractions obtained from liver and
muscle from subject A.II-3 using nondenaturing clear
native PAGE followed by western blot analysis using the
antibody against COXIV. Complex I assembly was ana-
lyzed in mitochondrial membrane fractions using non-
denaturing BN-PAGE followed by western blot analysis
using the antibody against NDUFS2, as described previ-
ously.24 In control samples, this assay shows only a
holocomplex at 1 MDa and a faint band at 400 kDa in
muscle samples, or at 230 kDa in fibroblasts.
2.4 | Western blot analysis of
mitochondrial proteins including SQOR
In subject A.II-3, complex IV integrity was evaluated
using an antibody against COXIV and complex I integ-
rity was evaluated using and antibody against NDUFB8
on western blot analysis. The amount of SQOR protein
was determined by western blot analysis on mitochon-
drial inner membrane fractions. The levels of H2S gen-
erating enzymes were evaluated by western blot
analysis using antibodies to CBS, CTH, MPST, and cys-
teine dioxygenase (CDO). All methods are described in
Supplemental Methods, and the source and specifica-
tions of all antibodies used are listed in Supplemental
Table S1.
2.5 | Analysis of SQOR enzyme activity
in liver, blood cells, and fibroblasts
The activity of SQOR was measured spectrophotometri-
cally in mitochondrial membrane fractions isolated from
liver and in lysates derived from peripheral blood mono-
nuclear cells (PBMCs) and from fibroblasts as previously
described for purified protein with the modifications
described in detail in Supplemental Methods.26 The reac-
tion uses sulfite as acceptor, following coenzyme Q1
reduction spectrophotometrically for 5 to 8 minutes at
278 nm. The kinetic parameters for human SQOR
enzyme were evaluated in human liver and fibroblast
samples.
2.6 | Protein modeling, purification, and
in vitro characterization of the human
SQOR mutant
The SQOR variant was mapped on the crystal structure of
the human SQOR protein (PDB: 6O1C)27 using PyMol.28
The human SQOR mutant protein p.Glu213Lys was
purified as reported previously for the wild type enzyme17
and the absorption spectrum and concentration estimated
as described in Supplemental Methods.
3 | RESULTS
3.1 | Case Reports
3.1.1 | Family A
The proband, subject II-3, was a 4-year-old girl born to
consanguineous Lehrerleut Hutterite parents, whose
grandparents were first cousins (Figure 2A). She had a
history of recovering slower from infections than her sib-
lings, but otherwise had no health concerns including no
gastrointestinal symptoms. At onset of the illness, during
the day she was more tired and vomited, and in the eve-
ning became rapidly encephalopathic with an episode of
tonic seizures. Upon presentation, she was comatose with
seizure-like movements, and Kussmaul breathing due to
lactic acidosis with pH 6.86, anion gap 31, lactate
17.3 mM, and uric acid 7.8 mg/dL. She developed shock,
respiratory insufficiency evolving into acute respiratory
distress syndrome, and multi-organ failure including liver
failure with increased prothrombin time INR 1.76 and
decreased clotting factors V and VII, mild hypoglycemia
47 mg/dL, mild hyperammonemia 112 μM, hypo-
albuminemia 2.9 g/L, but normal cortisol. With support-
ive therapy, the multiorgan failure stabilized rapidly over
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the next days, but coma (Glasgow coma scale [GCS]
5, decorticate posturing) without further seizures, hypo-
albuminemia (2.0-2.4 g/dL, normal 3.5-5.2 g/dL) with
otherwise normal liver function (transaminases AST
52-88, normal 15-50), and lactic acidosis (3-5 mM with
lactate/pyruvate ratio 17 and cerebrospinal fluid [CSF]
lactate 3.0 mM) persisted. Creatine kinase peaked at
722 U/L and remained mildly elevated. In subsequent
weeks, she had generalized hypotonia, and episodes of
neurostorming with tachycardia, hypertension, and
potentially pain, partially responding to treatment with
phenobarbital, levetiracetam, baclofen, diazepam, and
propranolol. She also developed a thrombus in the right
iliac to femoral vein requiring anticoagulation. She died a
few days after discharge.
Workup for infectious agents and toxins was
negative. The acylcarnitine profile, carnitine levels,
3-methylglutaconic acid, thiamin pyrophosphate level,
and plasma, urine and CSF amino acids levels were all
normal. Urine organic acids showed evidence of lactic
acidosis and ketosis. The electroencephalogram showed
diffuse slowing and lack of reactivity but no epileptiform
activity, and full cardiac evaluation including echocardio-
gram was normal. Brain MRI on the fourth day of illness
showed T2 prolongation and diffusion restriction in the
caudate, putamina, and globi pallidi (Figure 3A,B, white
arrowheads). There was also diffusion restriction in the
posterior part of the hippocampi (Figure 3B white
arrows), medial left temporal lobe, posterior inferior thal-
amus and the mammillary bodies (Figure 3C, white
notched arrowheads). Further, there was increased T2
and FLAIR signal in the cerebral peduncles, dentate
nuclei, and medial thalami, but brain stem, cerebellum,
cortex and white matter were normal. Brain magnetic
FIGURE 2 The SQOR pathogenic variant causes lack of protein and enzyme activity. A, In family A, a homozygous pathogenic variant
c.637G > A in exon 5 was identified in subjects A.II-2 and A.II-3 indicated by a filled circle, whereas subjects A.I-1, A.I-2, A.II-1, and A.II-4
are carriers for this pathogenic variant. B, In family B, the children are each homozygous for the variant c.446delT whereas the parents are
heterozygous carriers. C, Sanger sequencing results of both variants in subjects A.II-3 and B.II-3 are shown. D, The variant c.637G > A codes
for p.(Glu213Lys) which is mapped on the crystal structure of the human SQOR protein (PDB: 6O1C). The human SQOR monomer is shown
in gray ribbon with the flavin cofactor (yellow) and select residues (green) are shown in stick display. Glu213 is relatively surface exposed.
The close-up view shows that the side chain of Glu213 interacts with Arg217 and Arg222. The Glu213Lys mutation is predicted to disrupt
electrostatic stabilization of the arginine side chains. E, The SQOR protein (at approx. 50 kDa) is virtually absent in the patient liver and
strongly reduced in muscle as shown by western blot, using ANT (approx. 33 kDa) as a loading control in subject A.II-3 and in fibroblast of
subject B.II-3
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FIGURE 3 Brain magnetic resonance imaging in patients affected by SQOR deficiency. A-C, Axial diffusion-weighted brain MR images
of patient A.II-3 demonstrated symmetric restricted diffusion and edema involving the basal ganglia (white arrowheads), hippocampi (white
arrows), and mammillary bodies (white notched arrowheads). D-E, Axial diffusion-weighted brain MR images of patient A.II-2 reveal
predominantly left-sided restricted diffusion and edema of the cerebral cortices (white arrows) and symmetric restricted diffusion and edema
of the basal ganglia (white arrowheads). F, Single voxel proton MR spectroscopy (TE = 144) interrogating the left frontal lobe of patient A.
II-2 shows a large inverted lactate doublet at 1.3 ppm. G, In patient B.II-3 at age 4 4/12 years, axial T2-weighted brain MR image illustrated
patchy increased signal involving the splenium of the corpus callosum (white arrows). H-I, One year later for the same patient, axial
T2-weighted brain MR images show symmetric edema of the basal ganglia (white arrowheads) and anteromedial thalami (white notched
arrowheads), all of which had reduced diffusivity (not shown)
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resonance spectroscopy (MRS) over the right basal gang-
lia showed a large lactate peak six times larger than the
choline peak with a depressed N-acetylaspartate peak.
Biopsies of muscle and liver obtained for mitochondrial
evaluation had normal histology and electron microscopy
including of the mitochondrial architecture, and skin
biopsy electron microscopy was normal without evidence
of storage products. Nextgen sequencing of mitochondrial
DNA showed normal sequence without evidence for dele-
tions.29 Clinical exome sequencing was reported as nega-
tive without pathogenic variants identified in known
disease-causing genes.
Subject II-2, the older sister, was generally healthy,
but developed migraines 5 months prior to presentation.
At age 8 years, she developed a fever, nausea and
vomiting, and rapidly became comatose with apnea
requiring intubation. She had a large anion gap metabolic
acidosis with elevated lactate (peak 22 mmol/L) with lac-
tate/pyruvate ratio 51, with otherwise normal blood
values. She was tachycardic but otherwise had normal
cardiovascular function. She had depressed encephalo-
pathic function on EEG with spike waves over the left
frontal area. She died 3 days later.
On brain MRI, she had restricted diffusion of the left
frontoparietal cortex (Figure 3D,E, white arrows) and
right frontal cortex (not labeled). She had restricted diffu-
sion of caudate nuclei and putamina (Figure 3E). MRS of
the right basal ganglia revealed a large lactate inverted
doublet, increased choline and reduced N-acetylaspartate
signal (Figure 3F, white notched arrowhead).
3.1.2 | Family B
Subject II-3 is a male child born to consanguineous par-
ents of Turkish descent (cousins three times removed),
who has two healthy sisters (Figure 2B). At age
4 4/12 years, following gastroenteritis with diarrhea and
48 hours fasting, he presented encephalopathic with
decreased consciousness (GCS 12), dyskinesia and
mydriasis. On admission, he had mild hypoglycemia
50 mg/dL, mild hyperammonemia 100 μM, and meta-
bolic acidosis (pH 7.23, bicarbonate 12 mmol/L, base
excess −14 mmol/L) with elevated lactate 6.0 mmol/L,
and large ketones in urine. He had elevated creatine
phosphokinase, myoglobin, and transaminases. Urine
organic acids showed elevated lactate, ketones, and dicar-
boxylic acids. Serum acylcarnitine profile was consistent
with ketosis, and plasma amino acids showed elevations
of glutamine, lysine, proline, alanine, methionine, and
tyrosine with low citrulline, whereas CSF amino acids
were generally normal (Supplemental Table S2). Brain
MRI showed lesions of the splenium of the corpus
callosum (Figure 3G, white arrows), felt to be clinically
and radiographically consistent with mild encephalitis/
encephalopathy with reversible splenial lesion (MERS).
He improved with supportive therapy with intravenous
glucose and vitamins, and respiratory support was not
required after 2 days. Neurological signs of ptosis, strabis-
mus and ataxia persisted for a few months before recover-
ing, and the MRI lesions resolved after 4 months (not
shown).
At age 5 6/12 years, following diarrhea, fever and
fasting for 24 hours, he presented again encephalopathic
with decreased consciousness (GCS 10), mild hypoglyce-
mia 56 mg/dL, metabolic acidosis (pH 7.3, bicarbonate
14.2 mmol/L), elevated serum lactate 6.5 mmol/L, and in
urine elevated lactate, ketones, and dicarboxylic acids.
Plasma ammonia and muscle enzymes remained normal.
He recovered again with intravenous glucose administra-
tion. He was stable for several years but had learning dif-
ficulties and unilateral hearing loss.
At age 13 6/12 years, he had headache, asthenia
and anorexia for 36 hours, and became stuporous with-
out metabolic abnormalities. Brain MRI demonstrated
hyperintense lesions on T2-weighted imaging of the
caudate nuclei and putamina (Figure 3H-I, white
arrowheads), and the ventromedial aspects of the thal-
ami (Figure 3I, white notched arrowheads). Clinically,
he recovered completely within 2 weeks. He has
remained stable and generally healthy, except for easy
fatigue and learning difficulties with memory and
attention deficits.
A fasting test performed outside an acute episode
showed normal ketogenesis. Fibroblasts showed normal
enzyme activities of pyruvate carboxylase and succinyl-
CoA:3-keto acid coenzyme A transferase (SCOT), and
leucocytes had normal pyruvate dehydrogenase activity.
Molecular analysis of SLC19A3 and DLD was normal.
Methemoglobin levels were borderline elevated 2.1% and
2.9% (normal <2%).
3.2 | Mitochondrial functional studies
In subject A.II-3, analysis of the respiratory chain enzyme
complexes during an acute episode showed markedly
reduced complex IV activity with mildly decreased com-
plex II activity, more so in muscle than in liver (Table 1).
Surprisingly, BN PAGE analysis in muscle and liver
showed only a mild decrease in complex IV activity
within the range of normal variation (Figure 4A),
suggesting that it affected enzymatic activity more than
the structure or amount of the complex. In fibroblasts,
analysis of mitochondrial function was not possible as
cells from subject A.II-3 rapidly died on initial culture of
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unknown cause. Fibroblasts from subject B.II-3 grew well
and both respiratory chain enzyme activities and BN
PAGE with in-gel activity staining were normal
(Supplemental Table S3). We next evaluated directly if
the reduced activity evident in muscle and liver of subject
A.II-3 was due to a decrease in complex IV assembly.
Despite the strong decrease in complex IV activity, the
amount of a protein COXIV, as a representative of com-
plex IV subunits, was normal (Figure 4B). Following sep-
aration on a nondenaturing gel, normal amounts of fully
assembled complex IV were present in both muscle and
liver in the patient compared to three controls
(Figure 4C). The integrity of complex I assessed by the
amount of NDUFB8 as a marker subunit protein was
normal, as was its assembly assessed on a nondenaturing
gel (Figure 4D). Thus, the marked decrease in complex
IV activity was not caused by a problem in complex IV
biogenesis but rather its function.
3.3 | Genetic studies
The SQOR gene has 8 transcripts. The main protein cod-
ing transcript SQOR-201 has 10 exons. The transcript has
1701 bp and encodes a protein of 450 residues (Uniprot
Q9Y6N5). Whole exome studies in the proband A.II-3
showed a homozygous missense variant NM_021199.4:
c.637G > A, p.(Glu213Lys) in exon 5 of the SQOR gene,
genomic coordinates: hg19:chr15:45965982G > A, which
was confirmed by Sanger sequencing (Figure 2C). Her
sister A.II-2 was also homozygous for this variant and
both parents and two unaffected siblings were heterozy-
gous carriers (Figure 2A). Mutation Taster predicted this
variant to be disease-causing, Polyphen2 rated it as “pos-
sibly damaging” (score 0.915), and the scaled CADD
score was 34 (raw score 5.03). The SQOR p.Glu213Lys
variant is not reported in 1000 genomes or ExAC. In
gnomAD it was present in only one non-Finnish
European allele (minor allele frequency [MAF] in this
population 0.9 × 10−5, MAF 0.4 × 10−5 in all
populations). Phylogenetically, in most species, this
amino acid is an acidic residue, either a glutamic acid or
an aspartic acid; the mutation changes Glu213 to a basic
lysine.
Whole exome sequencing in subject B.II-3 revealed a
homozygous 1 bp deletion c.446delT, p.(Leu149Argfs*18),
genomic coordinates chr15:45962165delT, in exon 3 of
the SQOR gene, which was confirmed by Sanger sequenc-
ing (Figure 2C). This change predicts a loss of SQOR pro-
tein function possibly by nonsense-mediated decay of the
mutant RNA or by introducing a frameshift leading to a
premature truncation of protein translation. This variant
was present in heterozygous state in gnomAD only once
(MAF in this population 3.98 × 10−6). Sanger sequencing
TABLE 1 Respiratory chain enzyme activities in patient A.II.3
Activity (controls)
nmol min−1 mg protein−1 % of normal SD Activity/CS SD Activity/CO II SD
Muscle
Complex I 44.2 (23.6-74.8) 98% 0.1 176 (98-271) 0.1 888 (285-767) 1.9
Complex II 49.8 (49.0-133.4) 56% −1.8 198 (251-573) −1.8 NA NA
Complex III 20.3 (5.7-31.4) 117% 0.5 81 (19-72) 0.5 408 (45-369) 1.2
Complex II-III 45.7 (34.2-107.6) 72% −0.7 182 (172-472) −0.1 918 (549-1226) 0.7
Complex IV 0.4 (1.1-3.8) 15% −4.3 2 (4–23) −4.3 8 (11-68) −4.6
CS 251.7 (159.8-353.3) 98% 0.0 NA NA NA NA
Liver
Complex I 60.8 (14.4-56.0) 172% 1.5 600 (162-730) 0.9 264 (68-252) 1.3
Complex II 230.1 (174.7-309.8) 99% 0.1 2269 (2304-3311) −1.3 NA NA
Complex III 27.6 (13.8-27.6) 145% 3.1 273 (128-315) 0.6 120 (50-118) 1.0
Complex II-III 50.0 (10.8-107.3) 85% 0.4 493 (138-1062) −0.2 217 (62-383) 0.0
Complex IV 0.4 (0.5-3.2) 22% −1.8 4 (6-35) −2.4 2 (3-13) −2.5
CS 101.4 (59.5-109.3) 120% 0.1 NA NA NA NA
Note: The activities in muscle and liver tissue of each respiratory chain complex and of the combined complex II-III are shown expressed as nmol min−1 mg
protein−1 and as a ratio of the activity over citrate synthase activity (activity/CS) and as a ratio over the activity of complex II (activity/Co II). The patient's
values are followed by normal values in parentheses and the percentage of the average normal value is provided. The values are also expressed as standard
deviations (Z-score) of the log transformed values of controls, which are normally distributed. Activities that are reduced are highlighted in bold.
Abbreviations: CS, citrate synthase; CO II, complex II.
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revealed this change also in a homozygous state in the
asymptomatic sisters B.II-1 and B.II-2 (Figure 2B).
3.4 | SQOR functional studies
To understand the impact of the mutation on the protein,
the missense variant was mapped on the crystal structure
of human SQOR (Figure 2D). In the structure, Glu-213 is
remote from the active site, but resides in an α-helix and
is proximal to Arg-217 on the same helix and Arg-222 on
an adjacent α-helix. The side chain of Glu213 is predicted
to be involved in hydrogen bonding interactions with the
side chains of these two arginine residues (Figure 2D).
Introduction of the positively charged lysine in the
Glu213Lys mutant is predicted to disrupt these electro-
static interactions and destabilize the tertiary structure of
the protein. This structure suggests that the Glu213Lys
variant is likely to impair protein stability rather than
affect the catalytic mechanism.
Indeed, attempts to express the recombinant
Glu213Lys human SQOR protein in E. coli using the
methods employed for wild type proteins17 as well as
several modifications to growth and purification condi-
tions, repeatedly resulted in the majority of the recom-
binant protein aggregating in inclusion bodies. The
yield of soluble Glu213Lys SQOR protein was very low
and the protein appeared to be devoid of FAD as
assessed by the lack of an associated ultraviolet-visible
absorption spectrum.
FIGURE 4 Assembly and activity of mitochondrial complexes. A, Mitochondrial complexes were separated on a blue native (BN) gel
and assayed with in-gel activity staining in muscle (upper panel) and in liver (lower panel). A mild decrease in complex IV staining was
observed in muscle for patient A.II-3. B, In muscle and liver of patient A.II-3 a normal amount of the complex IV subunit COXIV is seen,
using citrate synthase as a loading control. C, Both muscle and liver exhibit normal levels of fully assembled complex IV in patient A.II-3
compared to control samples as revealed by blue gel followed by western blotting and detection with COXIV antibody. D, The assembly of
complex I is normal in patient A.II-3 compared to controls as identified by BN gel followed by western blotting and detection with an
antibody against NDUFS2
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Western blot analysis showed very low levels of
SQOR protein in muscle and liver tissues of subject A.II-3
and in fibroblasts of subject B.II-3 each compared to
three controls (Figure 2E).
To evaluate the functional impact, an SQOR enzyme
activity assay using sulfite as acceptor was developed using
liver tissue mitochondrial membrane fractions. The initial
rate was linearly dependent on lysate protein con-
centration over the range of 0.064 to 0.698 mg protein/mL
(final concentration) (r2 = .98) (Supplemental Figure S1A).
A KM of 2.2 ± 1.1 mM for sulfide and a Vmax of 27.8 ±
8.9 nmol min−1 mg protein−1 at 37C were observed
(Supplemental Figure S1C). The Vmax value was obtained
at sulfite concentrations of around 1 to 2 mM
(Supplemental Figure S1D), and at coenzyme Q1 concen-
trations of 100 μM (Supplemental Figure S1E). The coeffi-
cient of variation (COV) in the same liver tissue sample
was 14%. SQOR activity in subject A.II-3 liver was severely
reduced to 6% of the average of control values (0.71 ± 0.57
vs 11.42 ± 3.75 nmol min−1 mg protein−1, normal range
7.56-16.94; n = 5) (Supplementary Figure S2A).
To facilitate future diagnosis of SQOR deficiency, the
enzyme assay was modified for use with fibroblasts and
PBMCs. In fibroblasts, the initial rate of enzyme activity was
linear over a lysate protein concentration range from 0.01
to 0.34 mg protein mL−1 (r2 = .98) (Supplemental
Figure S1B). With control fibroblasts, a specific activity of
82.1 ± 21.2 nmol min−1 mg protein−1 (normal range
51.6-115.2; n = 12), COV 26% was obtained, whereas subject
B.II-3 fibroblasts had SQOR activity of 0.41 ± 0.16
nmol min−1 mg protein−1, 0.49% of average control value
(Supplemental Figure S2B). Analysis of control PBMCs
yielded a specific activity of 43.6 ± 2.1 nmol min−1 mg pro-
tein−1 (n = 8), COV 5%. Additional family members who
were found to be carriers for this mutation had 62%, 66%,
and 42% of mean control enzyme activity in PBMCs.
The homozygosity of the patient and the identifica-
tion of additional carriers in distant family members
suggested that Glu213Lys may represent a founder muta-
tion. Targeted mutation screening of de-identified DNA
samples of 40 subjects from this population identified
three carriers (carrier frequency P = .08 ± .04), implying
an affected incidence of 1 in 711. Untargeted population
analysis of the gnomAD database using predictive soft-
ware estimated a carrier frequency of P = .0023 (1 in
215), implying an incidence of 1 in 184 477 for biallelic
pathogenic variants.
4 | DISCUSSION
The Glu213Lys variant replaces an acidic with a basic
amino acid disrupting hydrogen bonding interactions
and destabilizing the SQOR protein. This protein instabil-
ity resulted in strongly reduced protein levels and
severely decreased enzyme activity, but not its complete
absence. The protein instability severely limited bacterial
expression of the recombinant Glu213Lys human SQOR
enzyme. These functional data confirm bioinformatic
predictions that this variant is pathogenic. It tracks with
deficient enzyme activity in the family and represents a
founder variant in the Lehrerleut Hutterite population
with a carrier frequency estimated to be as high as 1 in
13 based on limited screening of samples from this popu-
lation. The frameshift mutation in Family B likewise
resulted in severely reduced SQOR protein and enzyme
activity. These pathogenic variants limited the ability of
the patient to metabolize H2S, and presumably resulted
in episodic accumulation.
In all patients, acute symptoms were triggered by
infections and fasting, episodes associated with protein
catabolism. Outside acute events, our patients generally
appeared healthy, and likewise two siblings in Family B
have remained asymptomatic for prolonged time. They
did not exhibit symptoms such as chronic gastrointestinal
upset or a tendency for petechiae that have previously
been attributed to excess H2S in patients with pathogenic
variants in ETHE1 resulting in deficient persulfide
dioxygenase activity, the next step in the pathway.4 In
contrast to ETHE1 deficiency, ethylmalonic acid was not
noted in urine organic acid analysis, supporting that the
inhibition of short chain acyl-CoA dehydrogenase could
be due to accumulating coenzyme A-persulfide in the
intact SQOR protein in ETFE1 deficiency, but not in
SQOR deficiency.27 Chronic loss of complex IV protein
attributed to excess H2S in the mouse model of ETHE1
was also not observed in our patient.5 Rather, a func-
tional deficiency of complex IV activity was seen, while
the levels and assembly of complex IV appeared compa-
rable to controls. Deficient complex IV activity results in
an acute energy defect which in brain usually presents as
Leigh disease,21 although some genetic causes also
include myopathy or cardiomyopathy (eg, SCO2).30 In
our patients, the cardiovascular system appeared to be
relatively spared with cardiovascular symptoms limited
to transient hypotension and shock present only in the
context of multiorgan failure, which recovered with sup-
portive care. Acute H2S toxicity causes depression in car-
diac contractility and pulseless electrical activity.31 In an
animal model of acute H2S intoxication leading to 75%
mortality, 25% of surviving animals had neurological
lesions of neuronal necrosis of the cortex, putamen and
thalamus, which closely resembles the symptoms noted
in patient A.II-2.31 The striking involvement of the hippo-
campus and mammillary body in patient A.II-3 without
prolonged seizures likely represents the SQOR deficiency
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rather than an injury secondary to her poor state. In
mouse, SQOR protein is present in the hippocampus
(Maclean, unpublished observation25). Given the long
asymptomatic period in subject A.II-2 and subjects B.II-1
and B.II-2, we consider it possible that undiagnosed
patients exist, including in the Hutterite population.
The presence of normal amounts of cytochrome c oxi-
dase complex but severely reduced activity indicates that
the fundamental pathophysiological mechanism of SQOR
deficiency appears to be due to the resulting accumulation
of toxic metabolites, rather than disruption of complex IV
biogenesis. Acute illness is associated with catabolism and
associated endogenous protein breakdown. The resulting
increase in cysteine can increase H2S generation, which
would accumulate in the absence of sufficient SQOR
enzyme activity. At high levels, H2S can coordinate to the
iron in the heme a group of complex IV resulting in strong
inhibition.3 The complete absence of SQOR in yeast
impaired growth under obligate aerobic conditions,
whereas mutants that retain low levels of activity restored
oxidative growth, consistent with the detoxifying role
attributed to SQOR.32 We hypothesize that in our patients,
the low residual SQOR activity was likely sufficient to sup-
port H2S clearance during stable episodes but was insuffi-
cient during acute illness with catabolism resulting in H2S
accumulation and toxicity.
During acute H2S intoxication, two pools accumulate:
a soluble and diffusible pool of H2S gas in equilibrium
with the sulfide (HS−) anion, and a pool of sulfide bound
to metalloproteins (eg, hemes) and cysteine residues in a
variety of proteins.31, 33 It is unclear to what extent these
cysteine adducts can form nonenzymatically in the
absence of functional SQOR. The toxicity mechanism in
our patients might be partially different from that of acute
exogenous H2S intoxication. In our patient A.II-3, the
more severe reduction in complex IV activity was noted in
muscle tissue, where the sulfide generating enzymes could
not be detected, compared to liver tissue where the
enzymes were present and unchanged vs controls
(Supplemental Figure S2). This illustrates the importance
of great diffusibility of H2S, which is more soluble and dif-
fusible than oxygen or carbon dioxide.31 A large pool of
H2S bound to ferrous myoglobin has been proposed to
explain the sensitivity of muscle tissue to H2S toxicity.
34
SQOR has a wide tissue distribution including in neurons,
oligodendrocytes and vascular endothelial cells in brain,
likely reflecting a need to protect against this toxin that
readily diffuses across membranes.35, 36 Rapid diffusion of
H2S from tissue culture medium can explain the normal
complex IV activity in cultured fibroblasts.
Recognition of the enzymatic basis and intoxication of
the respiratory chain in the pathophysiology of SQOR defi-
ciency opens up possible therapeutic opportunities. First,
reduction in H2S production should be pursued. Since the
majority of H2S is generated from cysteine catabolism in
the body and gut microbiome,13 limiting dietary cysteine
and aggressive prevention of episodes triggering catabo-
lism by adequate provision of calories and avoidance of
prolonged fasting can be considered. Catabolic episodes
likely triggered the acute crisis in our patients. H2S is pro-
duced by γ-proteobacteria including certain gram-negative
and Clostridia species, which can be increased by omepra-
zole or lansoprazole,14 and can be therapeutically reduced
by treatment with metronidazole, similar to the treatment
of ETHE1 disorder.37 Certain vegetables, such as garlic,
onions, and certain cruciferous vegetables contain organic
polysulfides, which can directly release H2S and could be
avoided.14 Next, the toxic effects of accumulated H2S could
be mitigated. Toxicological studies have shown that hydro-
xocobalamin can bind H2S and pharmacological doses
have been used for detoxification during acute H2S poison-
ing, similar to the treatment of cyanide which shares a
similar pathophysiology.31, 33, 38 During acute symptom-
atic periods in illness, acute administration of very high
doses of hydroxocobalamin (70 mg/kg) may be required.
Given the rapidity of onset of life-threatening events,
which in our patients occurred within hours, preventive
daily subcutaneous administration of pharmacologic doses
of hydroxocobalamin, as is used to treat cobalamin C dis-
order, should be considered. Further, methylene blue has
been shown to reduce mortality due to acute H2S poison-
ing by reducing its mitochondrial toxicity.31, 39
In summary, we describe a new genetic cause of
Leigh disease associated with pathogenic variants in
SQOR, whereby intermittent accumulation of H2S results
in acute isolated complex IV deficiency. We developed an
enzyme assay that allows noninvasive measurement of
the enzyme activity, which is useful for diagnosis. Recog-
nition of SQOR deficiency as a cause of Leigh diseases is
clinically important since it suggests several treatment
modalities to prevent neurological complications.
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